Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Cyclin-dependent kinase pathways as targets for women's cancer treatment

Konecny, Gottfried E.

Current Opinion in Obstetrics and Gynecology: February 2016 - Volume 28 - Issue 1 - p 42–48
doi: 10.1097/GCO.0000000000000243
BREAST CANCER: Edited by Gottfried E. Konecny
Buy

Purpose of review In this article, we not only review the preclinical and clinical studies of cyclin-dependent kinase (CDK) 4/6 inhibitors in breast cancer, liposarcoma, mantel cell lymphoma, melanoma and germ cell tumors, but also examine promising preclinical data in glioblastoma, renal and ovarian cancer models that may provide directions for future development.

Recent findings Targeting CDKs has been the focus of considerable basic science and clinical research. The CDK 4/6 inhibitors are a novel class of therapeutics that target the CDK 4/6 kinases that promote transition through the cell cycle. Currently, palbociclib (PD0332991, Pfizer), abemaciclib (LY2835219, Lilly) and ribociclib (LEE011, Novartis) are being investigated in clinical trials. These oral agents offer the hope of clinical efficacy in many tumor types, and have been associated with minimal toxicity. Amplification/overexpression of cyclin D, loss of CDKN2A (p16) and amplification/overexpression of CDK4 are proposed biomarkers of improved response to CDK4/6 inhibition.

Summary Palbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma. Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development. Further preclinical and clinical research is needed to better understand mechanisms of resistance and develop rational combination therapies with other targeted agents.

David Geffen School of Medicine, University of California, Los Angeles, California, USA

Correspondence to Gottfried E. Konecny, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. E-mail: gkonecny@mednet.ucla.edu

Copyright © 2016 YEAR Wolters Kluwer Health, Inc. All rights reserved.